- Home
- MEIP vs SCNX Comparison
MEIP vs SCNX Comparison
Compare MEIP & SCNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MEIP
- SCNX
- Stock Information
- Founded
- MEIP 2000
- SCNX 2010
- Country
- MEIP United States
- SCNX United States
- Employees
- MEIP N/A
- SCNX N/A
- Industry
- MEIP Biotechnology: Pharmaceutical Preparations
- SCNX Other Pharmaceuticals
- Sector
- MEIP Health Care
- SCNX Health Care
- Exchange
- MEIP Nasdaq
- SCNX Nasdaq
- Market Cap
- MEIP 13.3M
- SCNX 14.4M
- IPO Year
- MEIP 2003
- SCNX 2020
- Fundamental
- Price
- MEIP $2.53
- SCNX $0.98
- Analyst Decision
- MEIP Hold
- SCNX
- Analyst Count
- MEIP 1
- SCNX 0
- Target Price
- MEIP N/A
- SCNX N/A
- AVG Volume (30 Days)
- MEIP 21.5K
- SCNX 129.8K
- Earning Date
- MEIP 05-13-2025
- SCNX 08-10-2025
- Dividend Yield
- MEIP N/A
- SCNX N/A
- EPS Growth
- MEIP N/A
- SCNX N/A
- EPS
- MEIP N/A
- SCNX N/A
- Revenue
- MEIP N/A
- SCNX $146,901.00
- Revenue This Year
- MEIP N/A
- SCNX N/A
- Revenue Next Year
- MEIP N/A
- SCNX N/A
- P/E Ratio
- MEIP N/A
- SCNX N/A
- Revenue Growth
- MEIP 33.76
- SCNX N/A
- 52 Week Low
- MEIP $1.46
- SCNX $0.69
- 52 Week High
- MEIP $4.10
- SCNX $23.77
- Technical
- Relative Strength Index (RSI)
- MEIP 78.43
- SCNX N/A
- Support Level
- MEIP $2.21
- SCNX N/A
- Resistance Level
- MEIP $2.95
- SCNX N/A
- Average True Range (ATR)
- MEIP 0.15
- SCNX 0.00
- MACD
- MEIP 0.05
- SCNX 0.00
- Stochastic Oscillator
- MEIP 81.48
- SCNX 0.00
About MEIP MEI Pharma Inc.
MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.
About SCNX Scienture Holdings Inc. Common Stock
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S.